Payment overview · 2025
General Payments
$513.43
21 reported records · 7 companies
Healthcare provider profile · identity verified
Norman Chow, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · LOS GATOS, CA · NPI 1871666248
Verified facts
What the public records show
CMS Open Payments records show Norman Chow, D.O. received $513.43 in general payments during 2025 across 21 reported records.
PFIZER INC. accounted for 21.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $111.83 | 21.8% | 5 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $100.53 | 19.6% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $91.75 | 17.9% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $83.80 | 16.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $55.84 | 10.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $43.88 | 8.6% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $25.80 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $513.43 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $111.83 | 5 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $100.53 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $91.75 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $83.80 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $50.87 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $43.88 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $28.36 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $27.48 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $25.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 197 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
197 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 440 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 426 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 390 | 89 |
| Furosemide | Furosemide | 293 | 58 |
| Metformin Hcl | Metformin Hcl | 276 | 57 |
| Lisinopril | Lisinopril | 246 | 59 |
| Losartan Potassium | Losartan Potassium | 205 | 49 |
| Eliquis | Apixaban | 197 | 32 |
| Gabapentin | Gabapentin | 180 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 159 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 152 | 27 |
| Clonazepam | Clonazepam | 144 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 135 | 58 |
| Simvastatin | Simvastatin | 125 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 112 | 25 |
| Omeprazole | Omeprazole | 102 | 31 |
| Risperidone | Risperidone | 99 | 26 |
| Azithromycin | Azithromycin | 91 | 68 |
| Trazodone Hcl | Trazodone Hcl | 85 | 27 |
| Mirtazapine | Mirtazapine | 82 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 82 | 14 |
| Carvedilol | Carvedilol | 80 | 18 |
| Sertraline Hcl | Sertraline Hcl | 80 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 79 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 77 | 23 |
| Famotidine | Famotidine | 74 | 20 |
| Olanzapine | Olanzapine | 74 | 13 |
| Potassium Chloride | Potassium Chloride | 69 | 16 |
| Lorazepam | Lorazepam | 68 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 64 | 12 |
| Donepezil Hcl | Donepezil Hcl | 60 | 18 |
| Finasteride | Finasteride | 59 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 15 |
| Januvia | Sitagliptin Phosphate | 58 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 57 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 33 |
| Glipizide | Glipizide | 56 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 32 |
| Cephalexin | Cephalexin | 54 | 40 |
| Memantine Hcl | Memantine Hcl | 52 | 11 |
| Divalproex Sodium | Divalproex Sodium | 50 | 15 |
| Warfarin Sodium | Warfarin Sodium | 49 | suppressed |
| Allopurinol | Allopurinol | 48 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 48 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 42 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 40 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 17 |
| Alendronate Sodium | Alendronate Sodium | 39 | suppressed |
| Levetiracetam | Levetiracetam | 38 | suppressed |
| Latanoprost | Latanoprost | 37 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 35 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | 13 |
| Prednisone | Prednisone | 31 | 18 |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 30 | suppressed |
| Haloperidol | Haloperidol | 30 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 30 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 29 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 28 | 19 |
| Benztropine Mesylate | Benztropine Mesylate | 27 | suppressed |
| Enulose | Lactulose | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | 13 |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 17 |
| Procrit | Epoetin Alfa | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Permethrin | Permethrin | 18 | 15 |
| Scopolamine | Scopolamine | 18 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Admelog Solostar | Insulin Lispro | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 15 |
| Lurasidone Hcl | Lurasidone Hcl | 15 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 15 | 11 |
| Sevelamer Hcl | Sevelamer Hcl | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 14 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Retacrit | Epoetin Alfa-Epbx | 14 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Griseofulvin | Griseofulvin, Microsize | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Clozapine | Clozapine | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $513.43 · 21 records | PFIZER INC. | CAPLYTA, ELIQUIS, Kerendia, Leqembi, MOUNJARO, QULIPTA, REXULTI, UBRELVY, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error